Helsinn in-licenses Zealand's ZP1846

Zealand (Glostrup, Denmark) granted Helsinn (Pazzallo, Switzerland) an exclusive, worldwide license to develop and commercialize ZP1846 to treat chemotherapy-induced diarrhea (CID). The glucagon-like ...